Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT2 | O75908 | 4/20 | 0.48 |
| ▸ | SOAT1 | P35610 | 4/20 | 0.48 |
| ▸ | NMBR | P28336 | 10/20 | 0.48 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6801610 | 0.94 | SOAT2 (0.49) | SOAT2SOAT1NMBRACAT1MME | |
| SCHEMBL6915779 | 0.93 | NMBR (0.44) | SOAT2SOAT1NMBR | |
| SCHEMBL6804298 | 0.79 | CYP1A2 (0.45) | MME | |
| SCHEMBL13328404 | 0.78 | NMBR (0.64) | SOAT2SOAT1NMBRACAT1 | |
| Lithium Ion SCHEMBL6804295 | 0.78 | MME (0.39) | NMBRMME | |
| SCHEMBL6203424 | 0.77 | PPARG (0.41) | NMBRMME | |
| SCHEMBL6805340 | 0.76 | NMBR (0.48) | SOAT2SOAT1NMBRACAT1 | |
| SCHEMBL6186309 | 0.73 | NMBR (0.51) | SOAT2SOAT1NMBRACAT1 | |
| SCHEMBL6218992 | 0.73 | NMBR (0.46) | SOAT2SOAT1NMBRACAT1 | |
| SCHEMBL6203402 | 0.73 | PPARG (0.46) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | SOAT2 3379/4885SOAT1 3334/4885NMBR 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.